Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In Process Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding

Avalo Therapeutics (AVTX) Shares Issued (2016 - 2025)

Avalo Therapeutics filings provide 11 years of Shares Issued readings, the most recent being -$40000.0 for Q3 2025.

On a quarterly basis, Shares Issued changed N/A to -$40000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $67.6 million, a 41.5% decrease, with the full-year FY2024 number at $68000.0, changed N/A from a year prior.
Shares Issued hit -$40000.0 in Q3 2025 for Avalo Therapeutics, down from $40000.0 in the prior quarter.
In the past five years, Shares Issued ranged from a high of $108.1 million in Q1 2024 to a low of -$37.4 million in Q3 2021.
Median Shares Issued over the past 5 years was $3.8 million (2024), compared with a mean of $17.2 million.
Biggest five-year swings in Shares Issued: plummeted 139.54% in 2022 and later skyrocketed 100995.52% in 2024.
Avalo Therapeutics' Shares Issued stood at $37.4 million in 2021, then plummeted by 139.54% to -$14.8 million in 2022, then surged by 99.55% to -$67000.0 in 2023, then skyrocketed by 100995.52% to $67.6 million in 2024, then plummeted by 100.06% to -$40000.0 in 2025.
The last three reported values for Shares Issued were -$40000.0 (Q3 2025), $40000.0 (Q2 2025), and $67.6 million (Q4 2024) per Business Quant data.